The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
Glutathione works as a frontline antioxidant, neutralizing these unstable molecules before they cause cellular damage
The FDA classifies it as a Category 2 bulk drug substance, noting potential safety concerns in unregulated compounding
Absorbance was measured at 532 nm and 600 nm using TBA in distilled water as a blank
A deeper understanding of the regulatory mechanisms and intracellular targets of chemotactic receptors is of great importance, as it could illuminate disease pathogenesis at the cellular level and aid in the identification of novel therapeutic targets across various diseases
